Industry Verticals »

All Categories

Insights »

About TMR »

Recombinant Factor C Assay Market

Recombinant Factor C Assay Market (Brand: PyroGene [PyroGene Bulk rFC {2,880 Tests} and PyroGene rFC {192 Tests}] and EndoNext [EndoZyme II, EndoZyme II GO, and EndoLisa]; and End User: Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies, and Contract Research Organizations [CROs]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Recombinant Factor C Assay a Sustainable Endotoxin Testing Solution

Recombinant factor C (rFC) assay is a synthetic equivalent of Factor C and is the first component of the horseshoe crab clotting cascade, which is activated in response to endotoxins. Moreover, the horseshoe crab blood can be collected only during a short time frame, thus limiting its supply considerably. Hence, healthcare companies in the recombinant factor C assay market are increasing their focus on rFC methods to help alleviate this challenge and improve outcomes.

Novel rFC methods are benefitting healthcare companies, as these companies can limit their reliance on animals or any other source materials. Hence, recombinant factor C assay is acquiring popularity as a sustainable solution for endotoxin testing. Such advancements have led to the growth of the recombinant factor C assay market, where the market is estimated to reach a revenue of ~US$ 28 Mn by the end of 2027. Analysts of Transparency Market Research (TMR) opine that rFC will gain recognition in the endotoxin testing industry for its accuracy and specificity, which is as good as the LAL (Limulus Amebocyte Lysate) assay.

recombinant factor c assay market infographic

To know the scope of our report Get a Sample on Recombinant Factor C Assay Market

PyroGene rFC Benefits Pharmaceutical Companies Due to Single-step Enzymatic Process

PyroGene™ recombinant factor C assay is gaining market prominence as a single-step enzymatic process as opposed to LAL assay that involves multiple procedural steps. As such, the PyroGene brand is anticipated to dictate the highest revenue as compared to EndoNext in the recombinant factor C assay market where the market is predicted to grow at a favorable CAGR of ~9% during the forecast period. Monitoring samples for contaminants play a pivotal role in pharmaceutical and medical device industries. This explains why the revenue of pharmaceutical companies is estimated to be the highest among all end users in the market landscape.

Traditional LAL testing is largely dependent on the blood of the horseshoe crab namely Limulus polyphemus. However, multiple enzymatic steps associated with LAL assay is majorly dependent on the availability of horseshoe crabs. Hence, companies in the recombinant factor C assay market are increasing their research spending in PyroGene recombinant factor C assay that can be associated with innovative software systems to gain a read-incubate-read sequence within the workflow.

Consolidated Nature of Market to Attract Attention of Healthcare Giants

LAL assays are considered as the gold standard for endotoxin testing. However, advantages of recombinant factor C assay are transforming the market landscape, which is dictated by only two major companies. Lonza Group— a leading Swiss multinational biotechnology company is increasing efforts to make its PyroGeneTM recombinant factor C assay a compendial method in Europe by collaborating with the European Pharmacopoeia. On the other hand, Hyglos GmbH— a bioMérieux company, which is a global player in in vitro diagnostics, is increasing efforts to reduce the incidence of false positives from ß-Glucan or interference due to colored or turbid samples. Thus, healthcare companies worldwide should tap opportunities in rFC, since the recombinant factor C assay market is consolidated.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies in the recombinant factor C assay market are reducing the pressure on LAL assays for innovations in monitoring samples for contaminants in pharmaceutical products. However, lack of long-term studies that validate rFC for combination testing of unknown samples, inter-laboratory, -operator, and -lot changes poses a barrier for market growth. Hence, pharmaceutical test users are increasing their efficacy in research studies to validate successful outcomes of rFC in specific products.

Effective FDA-approved Drug Builds Credibility of Healthcare Companies

Companies in the recombinant factor C assay market are gaining competitive edge over other players by introducing FDA-approved drugs using rFC. They are increasing efforts to experiment with humanized monoclonal antibodies such as galcanezumab for the prevention of migraine in adults. Novel rFC methods are being highly publicized as non-animal alternatives for the assessment of contaminating endotoxins in drugs. Though LAL is considered as the gold standard for endotoxin testing, official declarations by the FDA are validating the efficiency of PyroGene in the recombinant factor C assay market landscape. Thus, accuracy, sensitivity, and specificity of recombinant factor C assay is being considered at par with LAL methods.

recombinant factor c assay market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

Gaining FDA approval for drugs is essential in the recombinant factor C assay market. Advantages of rFC are grabbing the attention of commercial innovators in the field of recombinant technology to explore untapped business potentials.

rFC is ensuring the sustainable evolution of horseshoe crab species. However, it is still unsure whether rFC-based tests outshine LAL assays and other robust test systems. Hence, pharmaceutical test users should increase their efficacy in long-term research studies that validate the efficiency of rFC involving unknown samples and inter-laboratory, -operator, and -lot changes. They should increase research in comparative studies of rFC involving kinetic chromogenic LAL assays that help companies to boost their credibility in the market landscape.

Recombinant Factor C Assay Market: Overview

  • The global recombinant factor C assay market was valued at ~US$ 13 Mn in 2018 and is projected to expand at a considerable CAGR from 2019 to 2027. Endotoxin detection is a crucial step before the launch of pharmaceutical drugs, medical devices, and biotechnology products for human use. Recombinant factor C assay has been accepted as an alternative to LAL tests, which are widely employed for endotoxin testing. This growing acceptance as an alternative to LAL tests and its inclusion in the regulatory pharmacopoeias would contribute to the growth of the recombinant factor C assay market.   
  • Significant advantages offered by recombinant factor C assays, including cost advantages by aiding in reducing the operator risks by lowering the rate of invalid results and reduction of over 50% of the processing time as compared to the conventional microplate-based LAL tests, contribute to the growth of the recombinant factor C assays market
  • Productivity of the pharmaceutical industry has been significantly high, with an increase in the number of drugs approved annually. According to the U.S. FDA, in 2018, over 59 new drugs were approved in the U.S. Additionally, increase in demand for personalized medicine aids in the rise in the product approvals. This contributes to the growth of the recombinant factor C assays market.

Recombinant Factor C Assay Market: Segmentation

  • The global recombinant factor C assay market has been segmented based on brand, end user, and region
  • In terms of brand, the global recombinant factor C assay market has been categorized into PyroGene and EndoNext. The PyroGene brand is sub-segmented into PyroGene Bulk rFC (2,880 tests) and PyroGene rFC (192 tests). The EndoNext brand is sub-segmented into EndoZyme II, EndoZyme II GO, and EndoLisa. 
  • Based on end user, the global recombinant factor C assay market has been segregated into pharmaceutical companies, biotechnology companies, medical device companies, and contract research organizations (CROs). The pharmaceutical companies segment dominated the market in 2018, and is likely to remain dominant during the forecast period. Growth of the segment can be attributed to increase in approvals of pharmaceutical drugs globally. In addition, rise in demand for personalized medicines contributes to increase in manufacturing of pharmaceuticals, thereby leading to rise in the number of endotoxin detection tests conducted. This would contribute to the growth of the pharmaceutical companies segment in the recombinant factor C assay market.

Recombinant Factor C Assay Market: Regional Segmentation

  • In terms of region, the global recombinant factor C assay market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global recombinant factor C assay market in 2018 and the trend is expected to continue throughout the forecast period
  • The recombinant factor C assay market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period. Incorporation of recombinant factor C as a recognized endotoxin detection test by pharmacopoeias, and focus on conservation of the Limulus species in Asia Pacific contributes to the growth of the recombinant factor C assay market in the region.

Recombinant Factor C Assay Market: Major Players

  • Key players operating in the global recombinant factor C assay market are Lonza Group and Hyglos GmbH – a bioMérieux Company 
  • These players are focused on adopting inorganic growth strategies and product launches to strengthen their product portfolio. In June 2018, bioMérieux launched rapid ENDOZYME II GO, a new endotoxin test in the bioMérieux ENDONEXT range of recombinant horseshoe crab factor C assays. bioMérieux entered the market in 2016, through the acquisition of Hyglos, a company engaged in the development of recombinant factor C assays for endotoxin testing.

Global Recombinant Factor C Assay Market – Segmentation

Brand
  • PyroGene
    • PyroGene Bulk rFC (2,880 tests)
    • PyroGene rFC (192 tests)
  • EndoNext
    • EndoZyme II
    • EndoZyme II GO
    • EndoLisa

End User
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Contract Research Organizations (CROs)

Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of recombinant factor C assay market?

Recombinant factor C assay market to reach a revenue of ~US$ 28 Mn by the end of 2027

What are the key driving factors for the growth of the recombinant factor C assay market?

Recombinant factor C assay market is driven by rise in need for alternative endotoxin detection tests

Which region is expected to project the highest market share in the global recombinant factor C assay market?

North America dominated the global recombinant factor C assay market in 2018 and the trend is anticipated to continue during the forecast period

Which is the rising prominent segment in the recombinant factor C assay market?

The PyroGene brand segment is likely to account for a major share of the global recombinant factor C assay market during the forecast period

Who are the key players in the global recombinant factor C assay market?

Key players operating in the global recombinant factor C assay market include Lonza Group and Hyglos GmbH – a bioMérieux Company

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Acronyms

    3. Research Methodology

    4. Executive Summary: Global Recombinant Factor C Assay Market

    5. Market Overview

        5.1. Definition

        5.2. Market Indicators

        5.3. Market Dynamics

            5.3.1. Drivers

            5.3.2. Restraints

            5.3.3. Opportunities

        5.4. Global Recombinant Factor C Assay Market Revenue (US$ Mn) Forecast 2017–2027

        5.5. Global Recombinant Factor C Assay Market Outlook

    6. Key Insights

        6.1. Value Chain Analysis

        6.2. Key Industry Events

        6.3. Patent Analysis

        6.4. Product Features & USPs

        6.5. Overview of Pyrogen Testing Products Market

            6.5.1. Pyrogen Testing- Service Providers

            6.5.2. Pyrogen Testing Products Marketing, by Country/Region

        6.6. Overview of Limulus Amoebocyte Lysate (LAL) Tests

            6.6.1. Number of Assays Performed

            6.6.2. Cost per Assay and Turn Around Time

        6.7. Regulatory Scenario, by Country/Region

        6.8. Institutes Involved in Research Studies using Horseshoe Crabs

    7. Global Recombinant Factor C Assay Market Analysis and Forecast, by Brand 

        7.1. Introduction 

        7.2. Global Recombinant Factor C Assay Market Value Share Analysis, by Brand

        7.3. Global Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

            7.3.1. PyroGene

                7.3.1.1. PyroGene Bulk rFC (2,880 tests)

                7.3.1.2. PyroGene rFC (192 tests)

            7.3.2. EndoNext

                7.3.2.1. Endozyme II

                7.3.2.2. Endozyme II GO

                7.3.2.3. EndoLisa

        7.4. Global Recombinant Factor C Assay Market Attractiveness, by Brand 

    8. Global Recombinant Factor C Assay Market Analysis and Forecast, by End-user

        8.1. Introduction 

        8.2. Global Recombinant Factor C Assay Market Value Share Analysis, by End-user

        8.3. Global Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

            8.3.1. Pharmaceutical Companies

            8.3.2. Biotechnology Companies

            8.3.3. Medical Device Companies 

            8.3.4. Contract Research Organizations (CROs)

        8.4. Global Recombinant Factor C Assay Market Attractiveness, by End-user

    9. Global Recombinant Factor C Assay Market Analysis and Forecast, by Region 

        9.1. Regional Outlook

        9.2. Introduction

        9.3. Global Recombinant Factor C Assay Market Value Forecast, by Region

            9.3.1. North America

            9.3.2. Europe 

            9.3.3. Asia Pacific

            9.3.4. Latin America 

            9.3.5. Middle East & Africa

        9.4. Global Recombinant Factor C Assay Market Attractiveness, by Region

    10. North America Recombinant Factor C Assay Market Analysis and Forecast

        10.1.  Key Findings

        10.2.  North America Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

            10.2.1. PyroGene

                10.2.1.1. PyroGene Bulk rFC (2,880 tests)

                10.2.1.2. PyroGene rFC (192 tests)

            10.2.2. EndoNext

                10.2.2.1. Endozyme II

                10.2.2.2. Endozyme II GO

                10.2.2.3. EndoLisa

        10.3. North America Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

            10.3.1. Pharmaceutical Companies

            10.3.2. Biotechnology Companies

            10.3.3. Medical Device Companies 

            10.3.4. Contract Research Organizations (CROs)

        10.4. North America Recombinant Factor C Assay Market Value Forecast, by Country, 2017–2027

            10.4.1. U.S.

            10.4.2. Canada

        10.5. North America Recombinant Factor C Assay Market Attractiveness Analysis

            10.5.1. By Brand

            10.5.2. By End-user

            10.5.3. By Country

    11. Europe Recombinant Factor C Assay Market Analysis and Forecast

        11.1.  Key Findings

        11.2.  Europe Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

            11.2.1. PyroGene

                11.2.1.1. PyroGene Bulk rFC (2,880 tests)

                11.2.1.2. PyroGene rFC (192 tests)

            11.2.2. EndoNext

                11.2.2.1. Endozyme II

                11.2.2.2. Endozyme II GO

                11.2.2.3. EndoLisa

        11.3. Europe Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

            11.3.1. Pharmaceutical Companies

            11.3.2. Biotechnology Companies

            11.3.3. Medical Device Companies 

            11.3.4. Contract Research Organizations (CROs)

        11.4. Europe Recombinant Factor C Assay Market Value Forecast, by Country/Sub-region, 2017–2027

            11.4.1. U.K.

            11.4.2. Germany

            11.4.3. France

            11.4.4. Italy 

            11.4.5. Spain

            11.4.6. Rest of Europe

        11.5. Europe Recombinant Factor C Assay Market Attractiveness Analysis

            11.5.1. By Brand

            11.5.2. By End-user

            11.5.3. By Country/Sub-region

    12. Asia Pacific Recombinant Factor C Assay Market Analysis and Forecast

        12.1.  Key Findings

        12.2.  Asia Pacific Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

            12.2.1. PyroGene

                12.2.1.1. PyroGene Bulk rFC (2,880 tests)

                12.2.1.2. PyroGene rFC (192 tests)

            12.2.2. EndoNext

                12.2.2.1. Endozyme II

                12.2.2.2. Endozyme II GO

                12.2.2.3. EndoLisa

        12.3. Asia Pacific Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

            12.3.1. Pharmaceutical Companies

            12.3.2. Biotechnology Companies

            12.3.3. Medical Device Companies 

            12.3.4. Contract Research Organizations (CROs)

        12.4. Asia Pacific Recombinant Factor C Assay Market Value Forecast, by Country/Sub-region, 2017–2027

            12.4.1. China

            12.4.2. India

            12.4.3. Japan

            12.4.4. Australia & New Zealand 

            12.4.5. Rest of Asia Pacific 

        12.5. Asia Pacific Recombinant Factor C Assay Market Attractiveness Analysis

            12.5.1. By Brand

            12.5.2. By End-user

            12.5.3. By Country/Sub-region

    13. Latin America Recombinant Factor C Assay Market Analysis and Forecast

        13.1.  Key Findings

        13.2.  Latin America Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

            13.2.1. PyroGene

                13.2.1.1. PyroGene Bulk rFC (2,880 tests)

                13.2.1.2. PyroGene rFC (192 tests)

            13.2.2. EndoNext

                13.2.2.1. Endozyme II

                13.2.2.2. Endozyme II GO

                13.2.2.3. EndoLisa

        13.3. Latin America Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

            13.3.1. Pharmaceutical Companies

            13.3.2. Biotechnology Companies

            13.3.3. Medical Device Companies 

            13.3.4. Contract Research Organizations (CROs)

        13.4. Latin America Recombinant Factor C Assay Market Value Forecast, by Country/Sub-region, 2017–2027

            13.4.1. Brazil

            13.4.2. Mexico

            13.4.3. Rest of Latin America 

        13.5. Latin America Recombinant Factor C Assay Market Attractiveness Analysis

            13.5.1. By Product

            13.5.2. By End-user

            13.5.3. By Country/Sub-region

    14. Middle East & Africa Recombinant Factor C Assay Market Analysis and Forecast

        14.1.  Key Findings

        14.2.  Middle East & Africa Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

            14.2.1. PyroGene

                14.2.1.1. PyroGene Bulk rFC (2,880 tests)

                14.2.1.2. PyroGene rFC (192 tests)

            14.2.2. EndoNext

                14.2.2.1. Endozyme II

                14.2.2.2. Endozyme II GO

                14.2.2.3. EndoLisa

        14.3. Middle East & Africa Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

            14.3.1. Pharmaceutical Companies

            14.3.2. Biotechnology Companies

            14.3.3. Medical Device Companies 

            14.3.4. Contract Research Organizations (CROs)

        14.4. Middle East & Africa Recombinant Factor C Assay Market Value Forecast, by Country/Sub-region, 2017–2027

            14.4.1. GCC Countries

            14.4.2. South Africa

            14.4.3. Rest of Middle East & Africa 

        14.5. Middle East & Africa Recombinant Factor C Assay Market Attractiveness Analysis

            14.5.1. By Product

            14.5.2. By End-user

            14.5.3. By Country/Sub-region

    15. Competition Landscape

        15.1. Company Share Analysis

        15.2.   Company Profiles

            15.2.1. Lonza Group

                15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.1.2. Financial Overview

                15.2.1.3. Product Portfolio

                15.2.1.4. Strategic Overview

                15.2.1.5. SWOT Analysis

            15.2.2. Hyglos GmbH – a bioMérieux Company 

                15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.2.2. Financial Overview

                15.2.2.3. Product Portfolio

                15.2.2.4. Strategic Overview

                15.2.2.5. SWOT Analysis

    List of Tables

    Table 01: Patent Information – Pyrogene (Lonza)

    Table 02: Patent Information – EndoLisa

    Table 03: Patent Information – EndoZyme II GO

    Table 04: Patent Information – Recombinant Factor C Assay Market

    Table 05: Product Features & USPs – Recombinant Factor C Assays

    Table 06: Pyrogen Testing- Service Providers

    Table 07: Pyrogen Testing- Service Providers

    Table 08: Pyrogen Testing Products Marketing

    Table 09: Cost per Assay and Turn Around Time (LAL)

    Table 10: Institutes Involved in Research Studies using Horseshoe Crabs

    Table 11: Institutes Focused on Conversing Horseshoe Crabs

    Table 12: Pyrogen Testing Market Offerings, By Company

    Table 13: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

    Table 14: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

    Table 15: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

    Table 16: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

    Table 17: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Region, 2017–2027

    Table 18: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country, 2017–2027

    Table 19: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

    Table 20: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

    Table 21: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

    Table 22: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

    Table 23: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country/Sub-region, 2017–2027

    Table 24: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

    Table 25: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

    Table 26: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

    Table 27: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

    Table 28: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country/Sub-region, 2017–2027

    Table 29: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

    Table 30: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

    Table 31: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

    Table 32: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

    Table 33: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country/Sub-region, 2017–2027

    Table 34: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

    Table 35: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

    Table 36: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

    Table 37: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

    Table 38: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country/Sub-region, 2017–2027

    Table 39: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

    Table 40: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

    Table 41: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

    Table 42: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

    List of Figures

    Figure 01: Global Recombinant Factor C Assay Market Snapshot

    Figure 02: Global Recombinant Factor C Assay Market Value (US$ Thousand), by Region, 2018 and 2027

    Figure 03: Global Recombinant Factor C Assay Market Value (US$ Thousand) and Y-o-Y (%) Forecast, 2017–2027

    Figure 04: Global Recombinant Factor C Assay Market Value Share, by Brand, 2019

    Figure 05: Global Recombinant Factor C Assay Market Value Share, by End-user, 2019

    Figure 06: Global Recombinant Factor C Assay Market Value Share, by Region, 2019

    Figure 07: Value Chain Analysis – Recombinant Factor C Assay Market

    Figure 08: Key Industry Events – Recombinant Factor C Assays Market

    Figure 09: Regulatory Scenario – North America

    Figure 10: Regulatory Scenario – Europe

    Figure 11: Regulatory Scenario – Asia Pacific 

    Figure 12: Global Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

    Figure 13: Global Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

    Figure 14: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by PyroGene, 2017–2027

    Figure 15: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by EndoNext, 2017–2027

    Figure 16: Key Trends – By Brand

    Figure 17: Global Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 18: Global Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

    Figure 19: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by Pharmaceutical Companies, 2017–2027

    Figure 20: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by Biotechnology Companies, 2017–2027

    Figure 21: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by Medical Device Companies, 2017–2027

    Figure 22: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by Contract Research Organizations (CROs), 2017–2027

    Figure 23: Key Trends – By End-user

    Figure 24: Recombinant Factor C Assay Market – Regional Outlook

    Figure 25: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, 2017–2027

    Figure 26: Global Recombinant Factor C Assay Market Value Share Analysis, by Region, 2018 and 2027

    Figure 27: Global Recombinant Factor C Assay Market Attractiveness Analysis, by Region, 2019–2027

    Figure 28: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 29: North America Recombinant Factor C Assay Market Value Share Analysis, by Country, 2018 and 2027

    Figure 30: North America Recombinant Factor C Assay Market Attractiveness Analysis, by Country, 2019–2027

    Figure 31: North America Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

    Figure 32: North America Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

    Figure 33: North America Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 34: North America Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

    Figure 35: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 36: Europe Recombinant Factor C Assay Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 37: Europe Recombinant Factor C Assay Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 38: Europe Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

    Figure 39: Europe Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

    Figure 40: Europe Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 41: Europe Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

    Figure 42: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 43: Asia Pacific Recombinant Factor C Assay Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 44: Asia Pacific Recombinant Factor C Assay Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 45: Asia Pacific Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

    Figure 46: Asia Pacific Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

    Figure 47: Asia Pacific Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 48: Asia Pacific Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

    Figure 49: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 50: Latin America Recombinant Factor C Assay Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 51: Latin America Recombinant Factor C Assay Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 52: Latin America Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

    Figure 53: Latin America Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

    Figure 54: Latin America Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 55: Latin America Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

    Figure 56: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 57: Middle East & Africa Recombinant Factor C Assay Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 58: Middle East & Africa Recombinant Factor C Assay Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 59: Middle East & Africa Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

    Figure 60: Middle East & Africa Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

    Figure 61: Middle East & Africa Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 62: Middle East & Africa Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

    Figure 63: Global Recombinant Factor C Assay Market Analysis, by Top Company Ranking, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved

Recombinant Factor C Assay Market

Schedule a Call